Real-World Evidence of Automated Insulin Delivery System Use
Authors' conclusion
With larger and more diverse populations, and follow-up periods of longer duration (∼9 months vs. 3-6 months for pivotal trials), real-world retrospective analyses confirm pivotal trial findings.
Study context
- Population
- Nonpregnant individuals with T1D; studies published after 2018 with >5 individuals (PubMed, EMBASE)
- Participants
- 171,209 individuals20 studies
- Comparison
- Commercial automated insulin delivery (AID) use
- Outcome
- TIR 70-180 mg/dL (3.9-10.0 mmol/L) (primary outcome in 65% of studies)
Methodological detailsduplicate screening/extraction, PubMed and EMBASE searched; 80 studies identified, 20 included
- Duplicate screening/extraction
- PubMed and EMBASE searched; 80 studies identified, 20 included
Pooled result
As reported in the abstract
TIR 70-180 mg/dL
TIR primary outcome in % of studies
65%
Reports showing >10% change in TIR with AID
71%
Further pooled results
Change in hemoglobin A1c (HbA1c)
- Studies reporting HbA1c change
- 9
- Range of HbA1c change
- 0.1%-0.9%
- Decrease >0.2% achieved in studies describing HbA1c change
- two-thirds
Change in glucose management indicator (GMI)
- Studies reporting GMI change
- 4
- GMI reduction
- 0.1%-0.4%
- Decrease >0.2% achieved in articles describing GMI
- 80%
Time in automation
- Most systems had >90% time in automation
Safety
TBR <70 mg/dL (<3.9 mmol/L)
- Studies reporting TBR
- 16
- All but 1 study showed stable or reduced levels
Original publication
Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technol Ther. Published 5 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →